BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y

Key Takeaways BEAM reported Q4 loss of 10 cents per share as revenues jumped to $114.1 million, beating estimates.BEAM secured a $500M non-dilutive credit facility to support risto-cel launch in SCD.BEAM plans risto-cel BLA by the end of 2026. Its cash runway now extends into mid-2029.Beam Therapeutics (BEAM) incurred a loss of 10 cents per share in the fourth quarter of 2025 (excluding gain on sale of equity method investment), narrower than the Zacks Consensus Estimate of a loss of $1.13. The company had ...